Ralph Tiedt
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
van den Bent M, Zhang H, Balbin O, Vicente S, Cheng Y, Kirsilae T, Zhao S, Tiedt R, Rodón J, Tabatabai G, Jörger M, Lassman A, Wen P, Yung W, Sepulveda J, De Vos F, Azaro A, Wick W. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol 2019
Nov 27, 2019A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Nov 27, 2019J Neurooncol 2019
van den Bent Martin, Zhang Hefei, Balbin O Alejandro, Vicente Sergio, Cheng Yi, Kirsilae Tiina, Zhao Sylvia, Tiedt Ralph, Rodón Jordi, Tabatabai Ghazaleh, Jörger Markus, Lassman Andrew B, Wen Patrick Y, Yung W K Alfred, Sepulveda Juan, De Vos Filip, Azaro Analia, Wick Wolfgang
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
Kralovics R, Cazzola M, Pietra D, Passamonti F, Tichelli A, Tiedt R, Brutsche M, Buser A, Teo S, Skoda R. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106:3374-6.
Nov 15, 2005Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
Nov 15, 2005Blood 2005; 106:3374-6
Kralovics Robert, Cazzola Mario, Pietra Daniela, Passamonti Francesco, Tichelli André, Tiedt Ralph, Brutsche Martin, Buser Andreas S, Teo Soon-Siong, Skoda Radek C